Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 2914       
ORIGINAL ARTICLE
Year : 2012  |  Volume : 136  |  Issue : 6  |  Page : 979-984

Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin


1 National Institute for Research in Tuberculosis (ICMR), Chennai, India
2 Madras Medical College, Chennai, India

Correspondence Address:
Geetha Ramachandran
Scientist 'C', Department of Biochemistry & Clinical Pharmacology, National Institute for Research in Tuberculosis (ICMR), Mayor V.R. Ramanathan Road, Chetput, Chennai 600 031
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 23391793

Rights and PermissionsRights and Permissions

Background & objectives : Moxifloxacin (MFX) is reported to have promising antimycobacterial activity, and has a potential to shorten tuberculosis (TB) treatment. We undertook this study to examine the influence of rifampicin (RMP) and isoniazid (INH) on the steady state pharmacokinetics of MFX individually in healthy individuals. Methods: A baseline pharmacokinetic study of MFX (400 mg once daily) was conducted in 36 healthy adults and repeated after one week of daily MFX with either RMP (450/600 mg) (n = 18) or INH (300 mg) (n = 18). Plasma MFX concentrations were determined by a validated HPLC method. Results: Plasma peak concentration and exposure of MFX was significantly lower and plasma clearance significantly higher when combined with RMP (P<0.001). The C max to MIC and AUC 0-12 to MIC ratios of MFX were significantly lower during concomitant RMP (P<0.001). INH had no significant effect on the pharmacokinetics of MFX. Interpretation & conclusions : Concomitant RMP administration caused a significant decrease in C max and AUC 0-12 of MFX, the mean decreases being 26 and 29 per cent, respectively. It is uncertain whether this decrease would affect the treatment efficacy of MFX. Prospective studies in TB patients are needed to correlate MFX pharmacokinetics with treatment outcomes.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1087    
    Printed27    
    Emailed0    
    PDF Downloaded412    
    Comments [Add]    

Recommend this journal